Sigma reported 1H26 normalised revenue growth of 15% and EBIT growth of 19%. The sales result was strong but the modest operating leverage is a reminder of the inherently low gross margins in the business. Sales trends are strong but likely to slow from here. We expect LFL to remain double-digit in 2H26e, but then slip into single-digit territory for FY27e as the company laps higher growth and price inflation fades. Going forward, each 1% sales growth to translate into approximately 1.5% EBIT growth. Synergies will continue to help earnings over the next four years.

Sigma Warehouse reported its 1Q26 sales at its AGM. Chemist Warehouse like-for-like sales were up 14.7% for the quarter, an acceleration on FY25 trends. The company highlighted elevated sales of weight-loss drugs like Ozempic as a big contributor. We estimate the contribution is anywhere from 3%-5% of the LFL growth. We expect LFL sales to settle back at 11% in 2Q26e and 9.0% in 2H26e.

Sigma reported FY25 network sales growth for Chemist Warehouse of 14% and EBIT at $903 million, up 47%. The company reported a continuation of double-digit like-for-like sales growth with a lift in profit margins for the underlying Chemist Warehouse business. We forecast EBIT growth of 22% in FY26e ahead of revenue growth of 15%. Margins will be helped by penetration of Wagner private label, operating leverage from strong comp sales and the increasing synergies over the next four years.